GlassScriptPhysician profile
Ziad Berri
NPI 1881786770
$30,862.76
in general payments reported to CMS, 2019-2025
50 companies · $4,411 in 2025
The $4,411 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,125 · 2020: $3,260 · 2021: $4,204 · 2022: $4,105 · 2023: $4,864 · 2024: $4,894 · 2025: $4,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,148.81 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,312.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $3,225.48 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $2,484.67 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,982.58 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Cequr Corporation | $1,828.97 | 2023-2025 | Cequr Simplicity |
| Ironwood Pharmaceuticals, INC | $1,566.70 | 2019-2025 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,522.05 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $1,474.43 | 2021-2025 | |
| Lilly USA, LLC | $1,403.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,347.67 | 2020-2025 | Vraylar, Linzess, Viberzi |
| Pfizer INC. | $1,335.76 | 2019-2024 | |
| Astellas Pharma US INC | $807.65 | 2019-2024 | Veozah, Xtandi, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $711.85 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $661.02 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $653.86 | 2019-2025 | Rexulti |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Berri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.